9/6/2017 1:04:50 PM - Retesting support near its 50 DMA line ($60.10) with today&#39;s loss after wedging to a new 52-week high last week with gains lacking great volume conviction. The 8/23/17 mid-day report cautioned - <i>&quot;Reported earnings +29% on +19% sales revenues for the Jun &#39;17 quarter. Prior quarterly earnings increases were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases.&quot;</i><br><hr>8/23/2017 12:38:08 PM - Found support near its 50 DMA line, holding its ground near its 52-week high. Reported earnings +29% on +19% sales revenues for the Jun &#39;17 quarter. Prior quarterly earnings increases were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases.<br><hr>8/11/2017 12:20:18 PM - Consolidating near its 50 DMA line, holding its ground stubbornly near its 52-week high. Reported earnings +29% on +19% sales revenues for the Jun &#39;17 quarter. Prior quarterly earnings increases were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases.<br><hr>5/19/2017 12:27:03 PM - Holding its ground stubbornly near its 52-week high. Recently found support near its 50 DMA line. Reported earnings+31% on +19% sales revenues for the Mar &#39;17 quarter. Prior quarterly earnings increases were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases.<br><hr>4/28/2017 12:57:20 PM - Hitting another new 52-week high today while adding to a streak of gains. Recently found support near its 50 DMA line. Reported earnings+31% on +19% sales revenues for the Mar &#39;17 quarter. Prior quarterly earnings increases through Dec &#39;16 were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases.<br><hr>4/24/2017 11:50:30 AM - Hit a new 52-week high today. Recently found support near its 50 DMA line.  Last noted in the 2/17/17 mid-day report - <i>&quot;Quarterly earnings increases through Dec &#39;16 were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases. Annual earnings (A criteria) growth has not been strong and steady.&quot;</i><br><hr>2/17/2017 11:41:07 AM - Touched a new 52-week high today. Recently found support near its 50 DMA line.  Quarterly earnings increases through Dec &#39;16 were below the +25% minimum earnings guideline (C criteria) with sub par sales revenues increases. Annual earnings (A criteria) growth has not been strong and steady.<br><hr>10/15/2015 12:04:13 PM - Slumping back below its 50 and 200 DMA lines. The 10/12/15 mid-day report cautioned members - <em>&quot;Reported earnings +5% on -2% sales revenues for the Jun &#39;15 quarter, and prior quarters were below the +25% minimum earnings guideline (<strong>C</strong> criteria) with sub par sales revenues increases. Annual earnings (<strong>A</strong> criteria) growth has not been strong and steady.&quot; </em><br><hr>10/12/2015 12:26:11 PM - Rebounding above its 50 and 200 DMA lines toward its 52-week high. Reported earnings +5% on -2% sales revenues for the Jun &#39;15 quarter, and prior quarters were below the +25% minimum earnings guideline (<strong>C</strong> criteria) with sub par sales revenues increases. Annual earnings (<strong>A</strong> criteria) growth has not been strong and steady.<br><hr>8/6/2013 12:16:20 PM - Consolidating in a tight range for the past few weeks churning above average volume without making meaningful price progress. Reported earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) in the <strong>3</strong> latest quarters through Jun &#39;13 with sales revenues increases accelerating. Prior earnings history has not been strong and steady. Annual earnings (<strong>A</strong> criteria) growth has improved following a sharp downturn in FY &#39;09.<br><hr>8/1/2013 12:13:31 PM - Extended from any sound base. Reported earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) in the <strong>3</strong> latest quarters through Jun &#39;13 with sales revenues increases accelerating.  Annual earnings (<strong>A</strong> criteria) growth has improved following a sharp downturn in FY &#39;09.<br><hr>6/15/2007 12:30:36 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>6/14/2007 12:21:29 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>6/12/2007 12:16:30 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>6/11/2007 12:28:33 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>6/7/2007 12:37:19 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>6/6/2007 12:21:43 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/15/2007 12:18:20 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/14/2007 12:21:54 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/11/2007 12:29:37 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/4/2007 12:27:28 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/3/2007 12:24:00 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>4/30/2007 12:49:17 PM - Sales history is below the guidelines. Quarterly sales should be up 25% or more or accelerating over prior quarters.<br><hr>5/5/2006 12:24:48 PM - No base.<br><hr>4/7/2006 12:41:23 PM - Too extended from a sound base of support at this point to be considered buyable under the guidelines.<br><hr>